- Home
- GPAT vs DCTH Comparison
GPAT vs DCTH Comparison
Compare GPAT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPAT
- DCTH
- Stock Information
- Founded
- GPAT 2020
- DCTH 1988
- Country
- GPAT United States
- DCTH United States
- Employees
- GPAT N/A
- DCTH N/A
- Industry
- GPAT
- DCTH Medical/Dental Instruments
- Sector
- GPAT
- DCTH Health Care
- Exchange
- GPAT NYSE
- DCTH Nasdaq
- Market Cap
- GPAT 364.4M
- DCTH 387.2M
- IPO Year
- GPAT 2024
- DCTH N/A
- Fundamental
- Price
- GPAT $10.14
- DCTH $11.55
- Analyst Decision
- GPAT
- DCTH Strong Buy
- Analyst Count
- GPAT 0
- DCTH 4
- Target Price
- GPAT N/A
- DCTH $21.50
- AVG Volume (30 Days)
- GPAT 75.6K
- DCTH 372.6K
- Earning Date
- GPAT 01-01-0001
- DCTH 11-08-2024
- Dividend Yield
- GPAT N/A
- DCTH N/A
- EPS Growth
- GPAT N/A
- DCTH N/A
- EPS
- GPAT 0.30
- DCTH N/A
- Revenue
- GPAT N/A
- DCTH $22,644,000.00
- Revenue This Year
- GPAT N/A
- DCTH $1,605.13
- Revenue Next Year
- GPAT N/A
- DCTH $111.67
- P/E Ratio
- GPAT $33.50
- DCTH N/A
- Revenue Growth
- GPAT N/A
- DCTH 945.91
- 52 Week Low
- GPAT $9.98
- DCTH $3.43
- 52 Week High
- GPAT $10.16
- DCTH $13.30
- Technical
- Relative Strength Index (RSI)
- GPAT N/A
- DCTH 57.95
- Support Level
- GPAT N/A
- DCTH $11.67
- Resistance Level
- GPAT N/A
- DCTH $13.30
- Average True Range (ATR)
- GPAT 0.00
- DCTH 0.73
- MACD
- GPAT 0.00
- DCTH 0.01
- Stochastic Oscillator
- GPAT 0.00
- DCTH 34.60
About GPAT GP-ACT III ACQUISITION CORP
GP-Act III Acquisition Corp is a blank check company.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.